Etanercept FDA Link

A recombinant version of soluble human TNF receptor fused to an IgG FC fragment that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.

Also Known As:

Enbrel; Erelzi; Etanercept-szzs; Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein; TNF Receptor Type II-IgG Fusion Protein; TNFR-Fc Fusion Protein; TNR 001; TNR-001; TNT Receptor Fusion Protein; TNTR-Fc; Fusion Protein, TNFR-Fc; Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein; TNF Receptor Type II IgG Fusion Protein; TNFR Fc Fusion Protein; TNR001

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Immunoglobulin Fragments: 976
        Immunoglobulin Fc Fragments: 295
        Etanercept: 4749
        Immunoglobulin Constant Regions: 8
        Immunoglobulin Fc Fragments: 295
        Etanercept: 4749
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Immunoglobulin Fragments: 976
        Immunoglobulin Fc Fragments: 295
        Etanercept: 4749
        Immunoglobulin Constant Regions: 8
        Immunoglobulin Fc Fragments: 295
        Etanercept: 4749
  - Membrane Proteins: 10078
    - Cell Surface Receptors: 2125
      - Immunologic Receptors: 9
        Cytokine Receptors: 1620
        Tumor Necrosis Factor Receptors: 3685
        Etanercept: 4749
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Immunoglobulin Fragments: 976
        Immunoglobulin Fc Fragments: 295
        Etanercept: 4749
        Immunoglobulin Constant Regions: 8
        Immunoglobulin Fc Fragments: 295
        Etanercept: 4749
- Peptides: 82426
  - Peptide Fragments: 373
    - Immunoglobulin Fragments: 976
      - Immunoglobulin Fc Fragments: 295
        Etanercept: 4749

GISEA (Gruppo Italiano Studio Early Arthritis) Selected Research

GISEA (Gruppo Italiano Studio Early Arthritis) Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure